Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults

Vaccine

Volumn 31, Issue 5, 2013, Pages 770-776

  Greenberg, David P ^a   Robertson, Corwin A ^a   Noss, Michael J ^b   Blatter, Mark M ^c   Biedenbender, Rex ^d   Decker, Michael D ^a  

^a SANOFI PASTEUR   (France)

^b RADIANT RESEARCH   (United States)

^c Primary Physicians Research   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Adults; Immunogenicity; Influenza vaccine; Quadrivalent; Safety; United States

Indexed keywords

INFLUENZA VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; BENIGN PAROXYSMAL POSITIONAL VERTIGO; CONTROLLED STUDY; COUGHING; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE REACTION; MALAISE; MALE; MULTICENTER STUDY; OPEN STUDY; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; THORAX PAIN; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; DRUG TOXICITY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; MALE; MIDDLE AGED; SERUM; UNITED STATES; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84872611273     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.074     Document Type: Article

References (18)

1. Centers for Disease Control Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010, 59(August (RR-8)):1-62.
2. Monto A.S., Hornbuckle K., Ohmit S.E. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 2001, 154(July (2)):155-160.
3. Song J.Y., Cheong H.J., Hwang I.S., Choi W.S., Jo Y.M., Park D.W., et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010, 28(May (23)):3929-3935.
4. Sagawa M., Kojimahara N., Otsuka N., Kimura M., Yamaguchi N. Immune response to influenza vaccine in the elderly: association with nutritional and physical status. Geriatr Gerontol Int 2011, 11(January (1)):63-68.
5. McElhaney J.E. Influenza vaccine responses in older adults. Ageing Res Rev 2011, 10(July (3)):379-388.
6. Lang P.O., Govind S., Mitchell W.A., Siegrist C.A., Aspinall R. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing Res Rev 2011, 10(July (3)):389-395.
7. Nichol K.L., D'Heilly S.J., Greenberg M.E., Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. Clin Infect Dis 2009, 48(February (3)):292-298.
8. Monto A.S., Ansaldi F., Aspinall R., McElhaney J.E., Montano L.F., Nichol K.L., et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009, 27(August (37)):5043-5053.
9. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009, 200(July (2)):172-180.
10. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010, 28(September (Suppl. 4)):D45-D53.
11. Reed C., Meltzer M.I., Finelli L., Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30(March (11)):1993-1998.
12. The European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines. Harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). March 12, 1997. Available from: [cited 04.01.12]. http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf.
13. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the US. JAMA 2003, 289(January (2)):179-186.
14. Olson D.R., Heffernan R.T., Paladini M., Konty K., Weiss D., Mostashari F. Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York city. PLoS Med 2007, 4(August (8)):e247.
15. Li W.C., Shih S.R., Huang Y.C., Chen G.W., Chang S.C., Hsiao M.J., et al. Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan. J Clin Virol 2008, 42(May (1)):45-51.
16. Glezen W.P., Couch R.B., Taber L.H., Paredes A., Allison J.E., Frank A.L., et al. Epidemiologic observations of influenza B virus infections in Houston, Texas, 1976-1977. Am J Epidemiol 1980, 111(January (1)):13-22.
17. ® - adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Vaccine 2011, 29(November (47)):8696-8704.
18. Block S.L., Yi T., Sheldon E., Dubovsky F., Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011, 29(November (50)):9391-9397.